VV icon

The Worldwide Leader in Standardized Vision Testing

Clinical Evaluation of Diabetic Eye Disease

Diabetes is a systemic disease which damages blood vessels in the eye and, if unabated, can cause blindness. New data is now available which suggests that vision loss related to early vascular damage in the eyes of diabetic patients can be detected by contrast sensitivity evaluation. Even in patients who have 20/20 or better acuity, contrast sensitivity has been shown to be decreased. There are two key criteria to evaluate abnormality of contrast sensitivity in diabetic patients; below the normal range and asymmetry between eyes.

Below the Normal Range

20/20 diabetic patient with abnormal contrast sensitivity.
20/20 diabetic patient with abnormal contrast sensitivity.

If a patient has good acuity, 20/30 or better, then he or she should have good contrast sensitivity. One hallmark of diabetic eye disease is that patients fall outside the normal range (patch 3 or below in either Row B or Row C), even when acuity remains normal. The example below shows a 33 year old diabetic patient with 20/20 acuity. The contrast sensitivity is below the normal range even though this patient had no apparent retinopathy.

 

Asymmetry Between Eyes

Asymmetric contrast sensitivity in a 20/20 diabetic patient with no retinopathy
Asymmetric contrast sensitivity in a 20/20 diabetic patient with no retinopathy.

If a patient has the same acuity in both eyes, then contrast sensitivity should also be the same. A difference between eyes or asymmetry in CS is an early indicator of disease progression. The presence of a difference of 2 contrast levels (.3 log units) or more between eyes indicates that a significant loss in contrast sensitivity, even if both eyes are inside the normal range.

 

Relationship to Vasculature of the Diseased Eye

20/20 diabetic patient with areas of capillary dropout
20/20 diabetic patient with areas of capillary dropout. (From Arend et al. IOVS August 1997)

Published data by Arend et al (Arend et al. Invest Ophthalmol Vis Sci. Aug 1997) demonstrates that diabetic patients with good acuity may display vasculature damage in the retina, such as capillary drop-out or expansion of the foveal avascular zone.

These same patients display reductions in contrast sensitivity which are correlated to the level of vascular damage. Importantly, these retinal defects cannot be directly detected without the patient undergoing fluorescein angiography, an invasive procedure. These results suggests that contrast sensitivity may aid in screening patients and determining whether an angiogram is warranted.

 

Control of Treatment

Recent evidence (Mangouritsas et al. Ophthalmologic. April 1995) shows that contrast sensitivity falls during periods of artificially induced hyperglycemia in insulin dependent diabetic patients. These results suggests that contrast sensitivity may have a possible role in evaluating the treatment control of diabetic patients.

 

Refractive Error Must Be Corrected When Testing

It is very important to remember that the patients should be evaluated with best correction. Contrast sensitivity is very sensitive to refractive error. If a patient exhibits a deficit in contrast sensitivity, the correction of the patient should be re-checked to insure that the measured vision loss is not due to refractive error.

 

Most Useful in Younger Patients

Contrast sensitivity is most useful in the evaluation of diabetic eye disease in younger patients. Contrast sensitivity can be dramatically affected by the presence of cataracts or other eye anomalies. Younger patients are less likely to have other contaminating vision problems and as such the loss in contrast sensitivity can be used to assess the progression of diabetes. Remember to compare individual contrast sensitivity scores to the normal values of a similar age group. Old and younger normal values are available in another part of this website.

Featured Product

CSV-2000

CSV-2000 The first and only all-in-one digital vision testing device that offers the full range of vision tests, along with STANDARDIZED contrast sensitivity, glare and visual acuity.

feature-slide01

AcQviz Auto-Calibration

Includes the patented AcQviz technology that automatically measures monitor luminance and adjusts testing to the recognized FDA vision testing luminance standard of 85 cd/m2.


  • Standardized to the testing light level recommended by the FDA and ANSI

  • Easy-to-use remote control allows rapid integration into patient flow

feature-slide02

Full Range of Vision Tests

Includes the full range of vision tests, including acuity, astigmatism, convergence, color, depth, etc. and the proprietary VectorVision contrast sensitivity and glare tests.


  • Standardized to the testing light level recommended by the FDA and ANSI

  • Easy-to-use remote control allows rapid integration into patient flow

feature-slide03

Scientifically Validated Contrast Sensitivity Testing

Uses the same contrast and spatial frequency range that is validated by more than 100 scientific papers and provides the only published population age-norms.


  • Standardized to the testing light level recommended by the FDA and ANSI

  • Easy-to-use remote control allows rapid integration into patient flow

feature-slide01

Rapid Testing

Remote control provides the ability to easily switch between tests. All tests are designed specifically for a computerized format, thus making testing fast and easy.


  • Standardized to the testing light level recommended by the FDA and ANSI

  • Easy-to-use remote control allows rapid integration into patient flow

Why VectorVision?


As treatments evolve, so must the testing technology

Over the last 20 years, VectorVision testing equipment has become the worldwide benchmark for standardized contrast sensitivity, glare and ETDRS acuity testing.

Read our Reviews